Home LiteratureArticle Details
PMID: 27515050 Published · ppublish English Journal Article Review

Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.

Archives of pharmacal research ·Vol. 39 ·No. 8 ·2016-08-00 ·Pages 1085-99

Kim BH, Yi EH, Ye SK

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of a variety of genes to regulate important biological functions, including cell proliferation, differentiation, survival, angiogenesis, and immune response. Constitutive activation of STAT3 is important in oncogenic signaling and occurs at high frequency in human cancers, including diverse solid tumors and hematologic malignancies. Moreover, it is associated with a poor prognosis. The tumor microenvironment has recently been recognized as a key condition for cancer progression, invasion, angiogenesis, metastasis, and drug resistance by activation of STAT3 signaling. Therefore, understanding the biology associated with STAT3-mediated signaling cascades in the tumor microenvironment may offer the therapeutic potential to treat human cancers. This review presents an overview of the critical roles of STAT3 in the tumor microenvironment related to cancer biology and discusses recent advancements in the development of anticancer drugs that therapeutically inhibit STAT3 signaling cascades.

Keywords
Cancer Inflammation Signal transducer and activator of transcription 3 (STAT3) Tumor microenvironment
MeSH Terms
Animals Antineoplastic Agents/administration & dosage,metabolism Drug Delivery Systems/methods Humans Neoplasms/drug therapy,metabolism STAT3 Transcription Factor/antagonists & inhibitors,metabolism Tumor Microenvironment/drug effects,physiology
Chemicals
Antineoplastic Agents STAT3 Transcription Factor STAT3 protein, human
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Kim Byung-Hak
Department of Pharmacology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. | Biomedical Science Project (BK21PLUS), Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Yi Eun Hee
Department of Pharmacology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. | Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Ye Sang-Kyu
Department of Pharmacology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. sangkyu@snu.ac.kr. | Biomedical Science Project (BK21PLUS), Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. sangkyu@snu.ac.kr. | Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. sangkyu@snu.ac.kr. | Neuro-Immune Information Storage Network Research Center, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. sangkyu@snu.ac.kr.
Article Info
Journal
Archives of pharmacal research
Abbr.
Arch Pharm Res
ISSN
0253-6269
Published
2016-08-00
Epub
2016-00-11
Pages
1085-99
Language
English
Region
Korea (South)
NLM ID
8000036
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com